These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19312261)

  • 1. Evaluation of Drugs Used in the Treatment of Cardiovascular Diseases.
    Degraff AC
    Bull N Y Acad Med; 1942 Apr; 18(4):246-53. PubMed ID: 19312261
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinued cardiovascular drugs in 2013 and 2014.
    Zhao HP; Xiang BR
    Expert Opin Investig Drugs; 2015; 24(8):1083-92. PubMed ID: 26162717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
    Kaneko M; Narukawa M
    Clin Drug Investig; 2019 May; 39(5):469-476. PubMed ID: 30887418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research.
    Gasparyan AY; Ayvazyan L; Cocco G; Kitas GD
    Curr Pharm Des; 2012; 18(11):1543-55. PubMed ID: 22364138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety trials of incretin-based drugs: What do they mean?
    Yabe D; Seino Y
    J Diabetes Investig; 2017 May; 8(3):272-276. PubMed ID: 27612317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease, A Systematic Review.
    Eisavi M; Mazaheri E; Rezapour A; Vahedi S; Hadian M; Jafari A
    Int J Prev Med; 2021; 12():39. PubMed ID: 34249288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular monitoring of psychotropic drugs].
    Momomura S
    Seishin Shinkeigaku Zasshi; 2014; 116(2):123-9. PubMed ID: 24712272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinued drugs in 2007: cardiovascular drugs.
    Zhang XS; Xiang BR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1817-28. PubMed ID: 19012498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse reactions of antidepressant drugs and their application in patients with cardiovascular diseases.
    Tang M; Li X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 45(10):1228-1233. PubMed ID: 33268585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of new cardiovascular drugs. Relationships between considerations, professional characteristics, and prescribing.
    Wieringa NF; Denig P; de Graeff PA; Vos R
    Int J Technol Assess Health Care; 2001; 17(4):559-70. PubMed ID: 11758299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Administration of maximal or median doses of drugs in cardiovascular diseases?].
    Spácil J
    Vnitr Lek; 2003 Apr; 49(4):322-5; discussion 326-7. PubMed ID: 12793058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance and the cardiovascular system: two sides to every story.
    Keller GA; Di Girolamo G; Alvarez PA
    Curr Drug Saf; 2011 Sep; 6(4):224-9. PubMed ID: 22129317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could patents interfere with the development of a cardiovascular polypill?
    Beall RF; Schwalm JD; Huffman MD; McCready T; Yusuf S; Attaran A
    J Transl Med; 2016 Aug; 14(1):242. PubMed ID: 27538505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs.
    Kocadal K; Saygi S; Alkas FB; Sardas S
    North Clin Istanb; 2019; 6(2):196-202. PubMed ID: 31297490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.
    Leung JY; Barr AM; Procyshyn RM; Honer WG; Pang CC
    Pharmacol Ther; 2012 Aug; 135(2):113-22. PubMed ID: 22565090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of cardiovascular drugs.
    Fragasso G; Margonato A; Spoladore R; Lopaschuk GD
    Trends Cardiovasc Med; 2019 Apr; 29(3):176-187. PubMed ID: 30122289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular adverse effects of anti-inflammatory drugs.
    Roubille C; Martel-Pelletier J; Davy JM; Haraoui B; Pelletier JP
    Antiinflamm Antiallergy Agents Med Chem; 2013; 12(1):55-67. PubMed ID: 23286294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based study on well-being in the very old: the role of cardiovascular diseases and drugs.
    Westerbotn M; Agüero-Torres H; Fastbom J; Hillerås P
    Arch Gerontol Geriatr; 2005; 40(3):287-97. PubMed ID: 15814162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.